Marc Matrana, MD
Hematology & Oncology · New Orleans, LANPI 1598958316
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $656,592 of the $756,966 with a category attached, or 86.7%. It is spread thinly across 30 manufacturers, the largest accounting for just 23.6%. Reporting peaked in 2021 at $180,259 and has fallen 63.1% since, to $66,471 in 2025. Among hematology & oncology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 583 payments — averaging $1298.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$179K
- E.r. Squibb & Sons, L.L.C.$100K
- Exelixis Inc.$97K
- Eisai Inc.$67K
- Astellas Pharma US Inc$63K
- Johnson & Johnson$55K
- plus $196K from 24 others
Across 613 payments — averaging $6288.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2.5M
- Eisai Inc.$284K
- Pfizer$273K
- Incyte Corporation$137K
- Eli Lilly$116K
- AbbVie$96K
- plus $471K from 16 others
What the payments were for
- Consulting fees$74,12710%
- Speaking & faculty fees$656,59287%
- Travel & lodging$13,1442%
- Food & beverage$12,7312%
- Education$3730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 129 | $178,625 |
| E.r. Squibb & Sons, L.L.C. | 69 | $100,045 |
| Exelixis Inc. | 55 | $96,702 |
| Eisai Inc. | 62 | $67,234 |
| Astellas Pharma US Inc | 42 | $63,192 |
| Johnson & Johnson | 58 | $54,704 |
| Merck | 33 | $53,508 |
| EMD Serono, Inc. | 34 | $47,537 |
| Seagen Inc. | 29 | $39,614 |
| Pfizer | 10 | $12,239 |
| Genentech USA, Inc. | 9 | $11,281 |
| Daiichi Sankyo Inc. | 14 | $10,847 |
| Sanofi | 4 | $6,154 |
| Amgen | 2 | $3,665 |
| Novartis | 3 | $3,635 |
| Immunomedics, Inc. | 1 | $2,475 |
| Astellas Pharma Global Development | 2 | $1,905 |
| Bayer | 4 | $1,838 |
| Tempus AI, Inc | 9 | $551 |
| Novocure Inc. | 1 | $500 |
| Sanofi-aventis U.S. LLC | 2 | $175 |
| Novocure GmbH | 1 | $139 |
| Genentech, Inc. | 1 | $107 |
| AVEO Pharmaceuticals, Inc. | 1 | $91 |
| Bristol Myers Squibb | 2 | $72 |
| Beigene USA, Inc. | 2 | $33 |
| Boehringer Ingelheim | 1 | $32 |
| AbbVie | 1 | $30 |
| Gilead | 1 | $20 |
| Myovant Sciences Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$756,966 in reported general payments places this provider in the 95th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 24 | $571,184 |
| Abiraterone Acetate | 35 | $57,415 |
| Everolimus | 11 | $19,013 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 31 | $634 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 19 | $426 |
| Oxycodone Hcl | 15 | $295 |
| Tramadol Hcl | 27 | $191 |
| Prednisone | 37 | $163 |
| Levothyroxine Sodium | 29 | $140 |
| Gabapentin | 18 | $86 |
| Tamsulosin Hcl | 12 | $58 |
| Cyclobenzaprine Hcl | 11 | $54 |
| Lorazepam | 12 | $46 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $96,702 | $571,18424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 183 hematology & oncology providers in Louisiana.
Other hematology & oncology in New Orleans
- Pedro BarataNew Orleans$928K
- Maissaa JanbainNew Orleans$862K
- Lingling duNew Orleans$173K
- Cindy LeissingerNew Orleans$135K
- Carter DavisNew Orleans$61K
- Furhan YunusNew Orleans$55K
- Michelle LochNew Orleans$50K
- David MorrisonNew Orleans$23K
- Scott SonnierNew Orleans$20K
- Ralph MillettNew Orleans$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.